Bio-Rad Laboratories Inc (BIO)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -637,300 | -159,300 | -428,400 | -191,214 | -3,627,564 | -6,027,464 | -1,935,064 | -93,150 | 4,254,200 | 6,665,600 | 4,050,800 | 4,100,400 | 3,806,300 | 3,520,600 | 1,947,000 | 1,579,400 | 1,758,700 | 376,700 | 904,800 | 574,000 |
| Total stockholders’ equity | US$ in thousands | 8,741,130 | 8,416,200 | 8,446,890 | 9,763,720 | 9,615,250 | 8,477,470 | 8,945,040 | 10,203,300 | 13,685,200 | 15,332,400 | 11,594,900 | 10,609,100 | 9,889,690 | 8,825,140 | 7,353,400 | 6,293,080 | 5,756,840 | 5,131,190 | 5,486,810 | 4,863,860 |
| ROE | -7.29% | -1.89% | -5.07% | -1.96% | -37.73% | -71.10% | -21.63% | -0.91% | 31.09% | 43.47% | 34.94% | 38.65% | 38.49% | 39.89% | 26.48% | 25.10% | 30.55% | 7.34% | 16.49% | 11.80% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-637,300K ÷ $8,741,130K
= -7.29%
Bio-Rad Laboratories Inc.'s return on equity (ROE) has shown significant fluctuations over the past eight quarters. In Q4 2023, the ROE was reported at -7.29%, indicating that the company's net income generated a negative return compared to shareholders' equity. This was an improvement from the previous quarter, where the ROE was -1.82%.
However, the ROE has been mostly negative in recent quarters, with Q2 2022 and Q3 2022 showing particularly low ROE figures of -71.39% and -21.77% respectively. The sharp decline in ROE in Q2 2022 compared to Q1 2022 (-0.99%) and the subsequent improvement in Q3 2022 indicate significant volatility in the company's profitability.
It is important for stakeholders to closely monitor Bio-Rad Laboratories Inc.'s ROE performance to assess the efficiency of the company in generating returns for shareholders. The negative ROE figures suggest that the company may be facing challenges in maximizing shareholder wealth, and management may need to implement strategies to improve profitability and operational efficiency.
Peer comparison
Dec 31, 2023